Aerie Pharma (AERI) PT Lifted to $50 at Stifel on Strong Roclatan Results

September 15, 2016 11:52 AM EDT
Get Alerts AERI Hot Sheet
Price: $42.25 +2.05%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 22 | New: 54
Trade AERI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Stifel analyst Annabel Samimy reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $50.00 (from $40.00) after the company reported unequivocally positive results from its Phase 3 Roclatan MERCURY-1 study. This 90-day primary efficacy readout demonstrated statistically significant IOP-lowering of Roclatan over its Rhopressa and latanoprost components at clinically-meaningful levels of 1-3mmHg at all nine time points with no significant safety deviations from prior studies. Specifically, Roclatan was superior to latanoprost by 1.3-2.5mmHg (p<0.0001) and to Rhopressa by 1.8-3.0mmHg (p<0.0001).

Samimy commented, "mportantly, in a responder analysis, 46% of Roclatan patients achieved >35% reductions in IOP (p<0.0001) and 61% achieving <16mmHg at Day 90—key targets for ophthalmologists. We believe this clean readout of data goes far to de-risk the Roclatan/MERCURY program and we have confidence for consistent readouts at 12-months and for MERCURY-2. AERI looks to a year-end 2017 NDA filing for Roclatan."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $21.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities


Add Your Comment